{"id":"NCT01482910","sponsor":"Bayer","briefTitle":"VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)","officialTitle":"A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2014-03","completion":"2014-08","firstPosted":"2011-12-01","resultsPosted":"2015-03-13","lastUpdate":"2016-11-04"},"enrollment":304,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Degeneration"],"interventions":[{"type":"BIOLOGICAL","name":"Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","otherNames":[]},{"type":"DRUG","name":"Visudyne","otherNames":[]}],"arms":[{"label":"Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","type":"EXPERIMENTAL"},{"label":"PDT treatments","type":"ACTIVE_COMPARATOR"}],"summary":"This study will assess the efficacy and safety of intravitreally (IVT), i.e. directly into the eye administered VEGF Trap-Eye compared with photodynamic therapy (PDT) on visual function in Chinese subjects with age-related neovascular or \"wet\" age-related macular degeneration.\n\nSubjects will be randomized in a 3:1 ratio to either receive VEGF Trap-Eye or PDT. Both treatment groups will receive the other treatment as a sham procedure.","primaryOutcome":{"measure":"Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)","timeFrame":"Baseline and at week 28","effectByArm":[{"arm":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","deltaMin":14,"sd":12.1},{"arm":"PDT Treatments","deltaMin":3.9,"sd":14.6}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":14,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":228},"commonTop":["Macular fibrosis","Visual acuity reduced","Conjunctival haemorrhage","Retinal pigment epitheliopathy","Upper respiratory tract infection"]}}